NVO - Novo Nordisk A/S
57.09 0.00 (0.00%)
After hours: 4:25PM EST
| Previous close | 57.29 |
| Open | 57.15 |
| Bid | 57.10 x 1000 |
| Ask | 57.11 x 800 |
| Day's range | 57.04 - 57.42 |
| 52-week range | 43.12 - 57.93 |
| Volume | 827,056 |
| Avg. volume | 1,368,229 |
| Market cap | 134.638B |
| Beta (3Y monthly) | 0.61 |
| PE ratio (TTM) | 23.19 |
| EPS (TTM) | 2.46 |
| Earnings date | N/A |
| Forward dividend & yield | 1.25 (2.18%) |
| Ex-dividend date | 2019-03-22 |
| 1y target est | 57.90 |
- Zacks
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
- Zacks
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
- Zacks
Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss
Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.
- Zacks
The Zacks Analyst Blog Highlights: Citigroup, Novo Nordisk, BP, salesforce.com and TC Energy
The Zacks Analyst Blog Highlights: Citigroup, Novo Nordisk, BP, salesforce.com and TC Energy
- Reuters - UK Focus
UPDATE 2-European shares end week on cheery note after U.S. and Chinese data
European shares clocked their best day in over a week on Friday, as upbeat jobs data from the United States and a surprise bounce in Chinese manufacturing tempered nerves around slowing global growth. U.S. job growth slowed less than expected in October, while a private business survey indicated that China's factory activity unexpectedly expanded at the fastest pace in more than two years last month. The latest data out of China is in contrast to an official survey published on Thursday, which had factory activity shrinking for the sixth straight month in October.
- Reuters
Novo Nordisk nudges up 2019 sales outlook as new drugs excel
Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs. Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. The world's largest maker of diabetes drugs is betting on new treatments, including a first-of-its-kind tablet, to offset pricing pressure from competing insulins and U.S. lawmakers, who have been critical of rising drug costs.
- Zacks
Top Analyst Reports for Citigroup, Novo Nordisk & BP
Top Analyst Reports for Citigroup, Novo Nordisk & BP
- Simply Wall St.
Can Novo Nordisk A/S's (CPH:NOVO B) ROE Continue To Surpass The Industry Average?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- Zacks
PFE vs. NVO: Which Stock Is the Better Value Option?
PFE vs. NVO: Which Stock Is the Better Value Option?
- Zacks
The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices
The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices
- Zacks
Top Analyst Reports for Intel, Oracle & Novo Nordisk
Top Analyst Reports for Intel, Oracle & Novo Nordisk
- Zacks
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
- Zacks
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
- Zacks
Gilead-Galapagos Report Efficacy & Safety Results on RA Drug
Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.
- Zacks
bluebird Inks Genome Editing Research Deal With Novo Nordisk
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
- Zacks
Novo Nordisk Focuses on Pipeline Development Amid Competition
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
- Zacks
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
- Simply Wall St.
An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 25% Undervalued
Does the October share price for Novo Nordisk A/S (CPH:NOVO B) reflect what it's really worth? Today, we will estimate...
- Zacks
SNY or NVO: Which Is the Better Value Stock Right Now?
SNY vs. NVO: Which Stock Is the Better Value Option?
- Zacks
Enanta's Stock Down Despite NASH Drug Meeting Goal in Study
Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.
- Zacks
Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval
Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.
- Zacks
Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label
CHMP gives positive opinion to add cardiovascular risk reduction data from the REWIND outcomes study on the label of Lilly's (LLY) diabetes medicine, Trulicity.
- Reuters - UK Focus
UPDATE 2-European shares log fifth week of gains, Novo Nordisk shines
European stocks clocked their fifth straight week of gains on Friday with investors buying into the oil and gas and banking sectors, and Novo Nordisk rising after U.S. approval of its oral diabetes drug. Investors also sought refuge in the so-called defensive sectors such as utilities, real-estate and food and beverages ahead of a week packed with economic data. The United Nations (UN) general assembly will also provide clues on the fallout from attacks on Saudi oil facilities last weekend and indications of a potential meeting between the presidents of Iran and the United States.
- Reuters
Factbox: Britain's insulin providers prepare for Brexit fallout
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.
- Reuters
With a backup to the backup, insulin makers say they're primed for Brexit
For two men trained as scientists, the bosses of Britain's major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit. With Britain set to leave the European Union within weeks, Pinder Sahota at the world's biggest insulin maker Novo Nordisk, and Sanofi's Hugo Fry have rebuilt operations to withstand the most turbulent of events.
